You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 134 No. 12, December 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge: Challenges in Medical and Surgical Therapeutics
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Immunotherapy
 •Dermatology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effectiveness of Mycophenolate Mofetil in Refractory Pyoderma Gangrenosum

Hossein C. Nousari, MD; Wendy Lynch, MD; Grant J. Anhalt, MD
Department of Dermatology

Michelle Petri, MD, MPH
Division of Rheumatology, Johns Hopkins Medical Institutions, Baltimore, Md

Arch Dermatol. 1998;134:1509-1511.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 32-year-old white woman with systemic lupus erythematosus presented with a 2-year history of refractory pyoderma gangrenosum on the left pretibial area. The lesion eroded to expose underlying tendons and muscles, and involvement of deep structures caused mononeuritis, with resultant unilateral foot drop and intractable pain. Therapeutic regimens that had been used during this 2-year period but had failed to arrest progression included the following: prednisone, 1 mg/kg per day; prednisone in combination with azathioprine, 2.5 mg/kg per day; dapsone, 100 mg/d; oral cyclophosphamide, 2 mg/kg per day; and intralesional triamcinolone acetonide injections. Three intravenous pulses of methylprednisolone, 1 g each, as well as 2 intravenous cyclophosphamide pulses, 500 mg per pulse, were given to the patient without additional improvement. Immediately prior to the initiation of the new therapeutic regimen, the patient had been treated . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mycophenolate Mofetil as Therapy for Pyoderma Gangrenosum
Eaton and Callen
Arch Dermatol 2009;145:781-785.
ABSTRACT | FULL TEXT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate Mofetil Is an Effective Treatment for Peristomal Pyoderma Gangrenosum
Daniels and Callen
Arch Dermatol 2004;140:1427-1429.
FULL TEXT  

Treatment of Linear IgA Bullous Dermatosis of Childhood With Mycophenolate Mofetil
Farley-Li and Mancini
Arch Dermatol 2003;139:1121-1124.
FULL TEXT  

Mycophenolate Mofetil Is Effective in the Treatment of Atopic Dermatitis
Grundmann-Kollmann et al.
Arch Dermatol 2001;137:870-873.
ABSTRACT | FULL TEXT  

Recent advances: Dermatology
Foley
BMJ 2000;320:850-853.
FULL TEXT  

Successful Treatment of Resistant Hypertrophic and Bullous Lichen Planus With Mycophenolate Mofetil
Nousari et al.
Arch Dermatol 1999;135:1420-1421.
FULL TEXT  

The Role of Mycophenolate Mofetil in the Management of Pemphigus
Nousari et al.
Arch Dermatol 1999;135:853-854.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.